94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1574150
This article is part of the Research TopicNovel Molecular Targets in Cancer TherapyView all 28 articles
Downregulation of PAQR3 expression predicts poor prognosis of patients with pan-cancer: A metaanalysis
Provisionally accepted- 1Xingyi People's Hospital, Xingyi, China
- 2Taihe Hospital, Hubei University of Medicine, Shiyan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study aimed to evaluate the association between progestin and adipoQ receptor 3 (PAQR3) expression and survival outcomes, as well as disease progression, through a meta-analysis.A total of 1032 patients from nine eligible studies were included in the meta-analysis. The results demonstrated that high PAQR3 expression was significantly associated with improved overall survival (HR = 0.32; 95% CI = 0.19-0.56) and disease-free survival (HR = 0.35; 95% CI = 0.20-0.61) in pan-cancer patients. Downregulation of PAQR3 expression was significantly correlated with adverse clinicopathological characteristics, including lymph node metastasis (HR = 0.22; 95% CI = 0.06-0.82), higher histological grade (HR = 0.31; 95% CI = 0.12-0.81), advanced pathological stage (HR = 0.18; 95% CI = 0.05-0.66), tumor size (HR = 0.73; 95% CI = 0.36-1.5), distant metastasis (HR = 0.36; 95% CI = 0.07-1.82), and tumor invasion (HR = 0.18; 95% CI = 0.11-0.29). However, no significant associations were observed between PAQR3 expression and gender (HR = 0.94; 95% CI = 0.59-1.5) or age (HR = 1.10; 95% CI = 0.77-1.56). In conclusion, reduced PAQR3 expression in pan-cancer patients is associated with worse clinical outcomes and may promote cancer progression. These findings suggest that PAQR3 could serve as a potential prognostic biomarker and therapeutic target for cancer treatment.
Keywords: PAQR3, Cancer, Meta-analysis, biomarker, EGFR
Received: 10 Feb 2025; Accepted: 16 Apr 2025.
Copyright: © 2025 Zhai, Miao, Ai, Guo and Zha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qiang Guo, Taihe Hospital, Hubei University of Medicine, Shiyan, China
Ren-Zhong Zha, Xingyi People's Hospital, Xingyi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.